共 50 条
- [1] RANDOMIZED PHASE II TRIAL COMPARING THERAPY BASED ON TUMOR MOLECULAR PROFILING VERSUS CONVENTIONAL THERAPY IN REFRACTORY CANCER PATIENTS: SHIVA DESIGNANNALS OF ONCOLOGY, 2013, 24 : 36 - 36Le Tourneau, C.Kamal, M.Tredan, O.Gomez-Roca, C.Campone, M.Goncalves, A.Isambert, N.Gavoille, C.Gentien, D.Servant, N.Frio, T. RioPaoletti, X.
- [2] Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trialANNALS OF ONCOLOGY, 2017, 28 (03) : 590 - 596Belin, L.Kamal, M.Mauborgne, C.Plancher, C.Mulot, F.Delord, J. -P.Goncalves, A.Gavoille, C.Dubot, C.Isambert, N.Campone, M.Tredan, O.Ricci, F.Alt, M.Loirat, D.Sablin, M. -P.Paoletti, X.Servois, V.Le Tourneau, C.
- [3] Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial.CANCER RESEARCH, 2013, 73 (08)Le Tourneau, ChristopheScholl, SuzyMitrv, EmmanuelIsambert, NicolasTredan, OlivierDelord, Jean-PierreGoncalves, AntonyCampone, MarioGavoille, CelineServois, VincentMariani, OdetteVincent-Salomon, AnneGentien, DavidFrio, Thomas RioServant, NicolasRomejon, JulienBieche, IvanDelattre, OlivierPaoletti, XavierKamal, Maud
- [4] SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer-Overall Survival (OS) analysis.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Dureau, SylvainRicci, FrancescoAlt, MarieLoirat, DelphineSablin, Marie-PauleKamal, MaudBieche, IvanArmanet, SebastienDelord, Jean-PierreGoncalves, AnthonyGavoille, CelineDubot, CoralineIsambert, NicolasCampone, MarioTredan, OlivierMarous, MiguelleLatouche, AurelienBelin, LisaLe Tourneau, Christophe
- [5] Randomised phase II trial comparing therapy based on tumour molecular profiling versus conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialEUROPEAN JOURNAL OF CANCER, 2013, 49 : S194 - S194Le Tourneau, C.Mitry, E.Goncalves, A.Isambert, N.Gavoille, C.Tredan, O.Delord, J. P.Campone, M.Paoletti, X.Kamal, M.
- [6] SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer-PFS ratio from patients who crossed-over.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Le Tourneau, ChristopheKamal, MaudMauborgne, CecileMulot, FabriceDelord, Jean-PierreGoncalves, AnthonyGavoille, CelineDubot, CoralineIsambert, NicolasCampone, MarioTredan, OlivierRicci, FrancescoAlt, MarieLoirat, DelphineSablin, Marie-PaulePaoletti, XavierServois, VincentBelin, Lisa
- [7] Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialBritish Journal of Cancer, 2014, 111 : 17 - 24C Le TourneauX PaolettiN ServantI BiècheD GentienT Rio FrioA Vincent-SalomonV ServoisJ RomejonO MarianiV BernardP HuppeG PierronF MulotC CallensJ WongC MauborgneE RouleauC ReyesE HenryQ LeroyP GestraudP La RosaL EscalupE MitryO TrédanJ-P DelordM CamponeA GoncalvesN IsambertC GavoilleM Kamal
- [8] Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialBRITISH JOURNAL OF CANCER, 2014, 111 (01) : 17 - 24Le Tourneau, C.Paoletti, X.Servant, N.Bieche, I.Gentien, D.Frio, T. RioVincent-Salomon, A.Servois, V.Romejon, J.Mariani, O.Bernard, V.Huppe, P.Pierron, G.Mulot, F.Callens, C.Wong, J.Mauborgne, C.Rouleau, E.Reyes, C.Henry, E.Leroy, Q.Gestraud, P.La Rosa, P.Escalup, L.Mitry, E.Tredan, O.Delord, J-PCampone, M.Goncalves, A.Isambert, N.Gavoille, C.Kamal, M.
- [9] Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialLANCET ONCOLOGY, 2015, 16 (13): : 1324 - 1334Le Tourneau, ChristopheDelord, Jean-PierreGoncalves, AnthonyGavoille, CelineDubot, CoralineIsambert, NicolasCampone, MarioTredan, OlivierMassiani, Marie-AngeMauborgne, CecileArmanet, SebastienServant, NicolasBieche, IvanBernard, VirginieGentien, DavidJezequel, PascalAttignon, ValeryBoyault, SandrineVincent-Salomon, AnneServois, VincentSablin, Marie-PauleKamal, MaudPaoletti, Xavier
- [10] Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Mulicentar Phase II TrialJCO PRECISION ONCOLOGY, 2021, 5 : 133 - 144Chen, Alice P.Kummar, ShivaaniMoore, NancyRubinstein, Lawrence, VZhao, YingdongWilliams, P. MickeyPalmisano, AlidaSims, DavidCoyne, Geraldine O'SullivanRosenberger, Christina L.Simpson, MelRaghav, Kanwal P. S.Meric-Bernstam, FundaLeong, StephenWaqar, SaiamaFoster, Jared C.Konate, Mariam M.Das, BiswajitKarlovich, ChrisLih, Chih-JianPolley, EricSimon, RichardLi, Ming-ChungPiekarz, RichardDoroshow, James H.